Article info
PDFNeuromuscular
Short report
Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome
- Correspondence to Dr Satoshi Kuwabara, Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan; kuwabara-s{at}faculty.chiba-u.jp
Citation
Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome
Publication history
- Received December 31, 2012
- Revised February 3, 2013
- Accepted February 6, 2013
- First published March 5, 2013.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions